Barbara Weber - 01 Mar 2023 Form 4 Insider Report for Tango Therapeutics, Inc. (TNGX)

Role: Chief Executive Officer, Director
Signature: /s/ Douglas Barry, attorney-in-fact
Issuer symbol: TNGX
Transactions as of: 01 Mar 2023
Net transactions value: $0
Form type: 4
Filing time: 02 Mar 2023, 15:06:16 UTC
Previous filing: 17 Jun 2022
Next filing: 12 Jun 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TNGX	Common Stock	Award	$0	+89,545	+6.5%	$0.000000	1,457,137	01 Mar 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TNGX	Stock Option (Right to Buy)	Award	$0	+537,273		$0.000000	537,273	01 Mar 2023	Common Stock	537,273	$5.20	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest over a three year period at a rate of 1/3 on February 5, 2024, 1/3 on February 3, 2025 and 1/3 on February 2, 2026 subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
F2	This option shall vest and become exercisable over a four-year period, at a rate of 25% on January 1, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter.